Rosuvastatin

Brand names: Crestor · Active ingredient: Rosuvastatin

In short: Rosuvastatin tablets are indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events. As an adjunct to diet and exercise to reduce low-de

Forms & strengthsRosuvastatin tablets, USP: 5 mg of rosuvastatin: pink colored, oval shaped, biconvex, film coated tablets, debossed with SG on one side and 116 other side. …
LabelScieGen Pharmaceuticals, Inc.
Label updatedNov 13, 2026

What is Rosuvastatin used for?

Rosuvastatin tablets are indicated:

To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for these events.

As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C):

in adults with hypercholesterolemia.

and slow the progression of atherosclerosis in adults.

in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).

in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).

As an adjunct to diet for the treatment of adults with:

Primary dysbetalipoproteinemia.

Hypertriglyceridemia.

Rosuvastatin dosage

Administer rosuvastatin tablets orally as a single dose at any time of day, with or without food. Swallow the tablets whole.

Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets and adjust the dosage if necessary.

If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.

When taking rosuvastatin tablets with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin tablets at least 2 hours before the antacid

.

The dosage range for rosuvastatin tablets is 5 mg to 40 mg orally once daily.

The recommended dosage of rosuvastatin tablets depends on a patient’s indication for usage, LDL-C, and individual risk for CV events.

Dosage in Pediatric Patients 8 Years of Age and Older with HeFH

The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10 years and 5 mg to 20 mg orally once daily in patients aged 10 years and older.

Dosage in Pediatric Patients 7 Years of Age and Older with HoFH

The recommended dosage is 20 mg orally once daily.

Initiate rosuvastatin tablets at 5 mg orally once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of rosuvastatin tablets when treating Asian patients not adequately controlled at dosages up to 20 mg orally once daily

[see

Warnings and Precautions (5.1),

Use in Specific Populations (8.8), and

Clinical Pharmacology (12.3)].

In patients with severe renal impairment (CL

crless than 30 mL/min/1.73 m

2) not on hemodialysis, the recommended starting dosage is 5 mg orally once daily and should not exceed 10 mg orally once daily

.

There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.

Table 1 displays dosage modifications for rosuvastatin tablets due to drug interactions

.

Concomitantly Used Drug | Rosuvastatin tablets Dosage Modifications

Sofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvir | Avoid concomitant use.

Gemfibrozil | Avoid concomitant use. If use is unavoidable, initiate at 5 mg once daily and do not exceed 10 mg once daily.

Tafamidis | Avoid concomitant use. If use is unavoidable, initiate at 5 mg once daily and do not exceed 20 mg once daily.

Belumosudil | Do not exceed 5 mg once daily.

Cyclosporine | Do not exceed 5 mg once daily.

Darolutamide | Do not exceed 5 mg once daily.

Vadadustat | Do not exceed 5 mg once daily.

Additional Antiviral Medications

Simeprevir

Dasabuvir/ombitasvir/paritaprevir/ritonavir

Elbasvir/Grazoprevir

Sofosbuvir/Velpatasvir

Glecaprevir/Pibrentasvir

Atazanavir/Ritonavir

Lopinavir/Ritonavir | Initiate at 5 mg once daily. Do not exceed 10 mg once daily.

Capmatinib | Do not exceed 10 mg once daily.

Enasidenib | Do not exceed 10 mg once daily. …

How to take Rosuvastatin — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (

Patient Information).

Myopathy and Rhabdomyolysis

Advise patients that rosuvastatin tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over-the-counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever

.

Hepatic Dysfunction

Inform patients that rosuvastatin tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice

.

Increases in HbA1c and Fasting Serum Glucose Levels

Inform patients that increases in HbA1c and fasting serum glucose levels may occur with rosuvastatin tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices

.

Pregnancy

Advise pregnant patients and patients who can become pregnant of the potential risk to a fetus. …

Warnings & precautions

Do not take this medicine if: Rosuvastatin tablets are contraindicated in patients with:

Acute liver failure or decompensated cirrhosis

.

Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets

.

Rosuvastatin may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis with statins, including rosuvastatin.

Risk Factors for Myopathy

Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher rosuvastatin dosage. Asian patients on rosuvastatin may be at higher risk for myopathy

. The myopathy risk is greater in patients taking rosuvastatin 40 mg daily compared with lower rosuvastatin dosages.

Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis

Rosuvastatin dosage modifications are recommended for patients taking certain medications; concomitant use with certain other medications should be avoided .

Discontinue rosuvastatin if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if rosuvastatin is discontinued. Temporarily discontinue rosuvastatin in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).

Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the rosuvastatin dosage. …

Rosuvastatin side effects

The following important adverse reactions are described below and elsewhere in the labeling:

Myopathy and Rhabdomyolysis

Immune-Mediated Necrotizing Myopathy

Hepatic Dysfunction

Proteinuria and Hematuria

Increases in HbA1c and Fasting Serum Glucose Levels

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse reactions reported in ≥2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 2. These studies had a treatment duration of up to 12 weeks.

Adverse Reactions | Placebo

N=382% | Rosuvastatin

5 mg

N=291% | Rosuvastatin

10 mg

N=283% | Rosuvastatin

20 mg

N=64% | Rosuvastatin

40 mg

N=106% | Total Rosuvastatin

5 mg to 40 mg

N=744%

Headache | 5.0 | 5.5 | 4.9 | 3.1 | 8.5 | 5.5

Nausea | 3.1 | 3.8 | 3.5 | 6.3 | 0 | 3.4

Myalgia | 1.3 | 3.1 | 2.1 | 6.3 | 1.9 | 2.8

Asthenia | 2.6 | 2.4 | 3.2 | 4.7 | 0.9 | 2.7

Constipation | 2.4 | 2.1 | 2.1 | 4.7 | 2.8 | 2.4

Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. …

Drug interactions

Rosuvastatin is a substrate of CYP2C9 and transporters (such as OATP1B1, BCRP). Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. Table 5 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with rosuvastatin and instructions for preventing or managing them

.

Sofosbuvir/velpatasvir/voxilaprevir or Ledipasvir/sofosbuvir

Prevention or Management: | Avoid concomitant use with rosuvastatin.

Mechanism and Clinical Effect(s): | Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis.

Gemfibrozil

Prevention or Management: | Avoid concomitant use of gemfibrozil with rosuvastatin. If use is unavoidable, initiate rosuvastatin at 5 mg once daily and do not exceed a dosage of rosuvastatin 10 mg once daily.

Mechanism and Clinical Effect(s): | Gemfibrozil significantly increased rosuvastatin exposure and gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use.

Tafamidis

Prevention or Management: | Avoid concomitant use of tafamidis with rosuvastatin. …

About this medicine

Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor.

The chemical name for rosuvastatin calcium, USP is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2­ [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:

The empirical formula for rosuvastatin calcium is (C

22H

27FN

3O

6S)

2Ca and the molecular weight is 1001.14. Rosuvastatin calcium, USP is a white to almost white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 1.4 at pH of 7.0. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ee4933c5-0d97-494d-ac0f-2083e0100836. Read the full official label on DailyMed.

Related medicines

Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Simvastatin Spironolactone Pravastatin